Patent · US Active

Identification, assessment, and therapy of cancers with innate or acquired resistance to ALK inhibitors

US9018230B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

Jichi Medical University · JP

Inventors

Hiroyuki Mano · Tokyo, JP
Young L. Choi · Tokyo, JP
Manabu Soda · Tochigi, JP

Key dates

Filing date	Feb 4, 2011
Grant date	Apr 28, 2015
Priority date	—
Expiry date	Feb 4, 2031

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/9121
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) positive for ALK mutations are likely to respond to treatment with an ALK inhibitor and/or whether a patient having such cancer(s) is likely to have a relatively slower disease progression. Further described are methods for prognosing a time course of disease in a subject having such cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.